Peptide Comparison
BPC-157vsKPV (Alpha-MSH Fragment)
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation
At a Glance
Quick
comparison
Dose Range
BPC-157
250–500 mcg
KPV (Alpha-MSH Fragment)
200 mcg–1500 mcg mcg
Frequency
BPC-157
Once daily
KPV (Alpha-MSH Fragment)
Once daily
Administration
BPC-157
Subcutaneous injection
KPV (Alpha-MSH Fragment)
Oral
Cycle Length
BPC-157
4-6 weeks
KPV (Alpha-MSH Fragment)
Ongoing/indefinite
Onset Speed
BPC-157
Moderate (1-2 weeks)
KPV (Alpha-MSH Fragment)
Moderate (1-2 weeks)
Evidence Level
BPC-157
Strong preclinical (extensive animal studies)
KPV (Alpha-MSH Fragment)
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Anti-Inflammatory
Gut Health
Healing & Recovery
Technical Data
Compound
specifications
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
KPV (Alpha-MSH Fragment)
Molecular Formula
C16H30N4O4
Molecular Weight
342.43 Da
Half-Life
Short peptide half-life; improved by nanoparticle and hydrogel formulations
Bioavailability
Oral uptake via PepT1 transporter; enhanced by nanoparticle formulations
CAS Number
67727-97-3
Protocols
Dosing
tiers
BPC-157
KPV (Alpha-MSH Fragment)
Applications
Best
suited for
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
KPV (Alpha-MSH Fragment)
Inflammatory bowel disease research
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gut anti-inflammatory therapy development
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Skin inflammation and wound healing
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated inflammation studies
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
KPV (Alpha-MSH Fragment)
Common
- Injection Site Reaction
- Mild GI Effects
- Transient Skin Effects
- Mild Immune Modulation
- Peptide Stability Concerns
Uncommon
- Theoretical Immunosuppression
Serious
- Immune Tolerance Development
Research Status
Safety
& evidence
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
KPV (Alpha-MSH Fragment)
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.
Contraindications
- xNot approved for human clinical use
- xUnknown interactions with immunosuppressive medications
- xInsufficient safety data for pregnancy and lactation
- xPotential melanocortin receptor effects in susceptible individuals
Decision Guide
Which is
right for you?
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Choose KPV (Alpha-MSH Fragment) if...
- Inflammatory bowel disease research
- Gut anti-inflammatory therapy development
- Skin inflammation and wound healing
- Cytokine-mediated inflammation studies